Results 41 to 50 of about 15,930 (153)

Creatinine–Cystatin C Discrepancy and Renal Transporter Polymorphisms in Japanese Patients with Breast Cancer Receiving Abemaciclib

Clinical Pharmacology &Therapeutics, EarlyView.
Abemaciclib increases serum creatinine by inhibiting renal tubular transporters rather than reducing true glomerular filtration rate, a phenomenon known as pseudo‐acute kidney injury. Creatinine–cystatin C discrepancy and genetic determinants of this elevation remain insufficiently characterized in Japanese patients.
Hiroaki Watanabe, Keita Hirai, Takaaki Oba, Mayu Ono, Ken‐ichi Ito, Takafumi Naito   +5 more
wiley   +1 more source

A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer

npj Breast Cancer
Palbociclib combined with endocrine therapy is approved for treating patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer; however, data on palbociclib combined with tamoxifen are ...
Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori   +33 more
doaj   +1 more source

miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models

Molecular Therapy: Nucleic Acids, 2022
Palbociclib is in early-stage clinical testing in advanced hepatocellular carcinoma (HCC). Here, we investigated whether the anti-tumor activity of palbociclib, which prevents the CDK4/6-mediated phosphorylation of RB1 but simultaneously activates AKT ...
Elisa Callegari, Paola Guerriero, Cristian Bassi, Lucilla D’Abundo, Antonio Frassoldati, Edi Simoni, Laura Astolfi, Enrico Maria Silini, Silvia Sabbioni, Massimo Negrini   +9 more
doaj   +1 more source

Risk Factors Influencing Efficacy and Prognosis Evaluation of Neoadjuvant Systemic Therapy in Triple‐Positive Breast Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT To identify the determinants of the response to neoadjuvant systemic therapy (NST) in triple‐positive breast cancer (TPBC), we retrospectively enrolled 520 patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer who were treated at The First Affiliated Hospital of Chongqing Medical University between January 2015 ...
Lin‐Rui Miao, Hao Liu, Hai‐Ying Yu, Jian Chen, Ming‐Yu Yang, Ya‐Lan Zhang, Gang Tu, Ling‐Feng Tang   +7 more
wiley   +1 more source

The G Protein Estrogen Receptor (GPER) is involved in the resistance to the CDK4/6 inhibitor palbociclib in breast cancer

Journal of Experimental & Clinical Cancer Research
Background The cyclin D1-cyclin dependent kinases (CDK)4/6 inhibitor palbociclib in combination with endocrine therapy shows remarkable efficacy in the management of estrogen receptor (ER)-positive and HER2-negative advanced breast cancer (BC ...
Marianna Talia, Francesca Cirillo, Domenica Scordamaglia, Marika Di Dio, Azzurra Zicarelli, Salvatore De Rosis, Anna Maria Miglietta, Carlo Capalbo, Ernestina Marianna De Francesco, Antonino Belfiore, Fedora Grande, Bruno Rizzuti, Maria Antonietta Occhiuzzi, Giancarlo Fortino, Antonella Guzzo, Gianluigi Greco, Marcello Maggiolini, Rosamaria Lappano   +17 more
doaj   +1 more source

Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy

Frontiers in Pharmacology, 2023
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib is an emerging cancer therapeutic that just recently gained Food and Drug Administration approval for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor (
Claudia Arndt, Claudia Arndt, Antje Tunger, Antje Tunger, Rebekka Wehner, Rebekka Wehner, Rebekka Wehner, Rebecca Rothe, Rebecca Rothe, Eleni Kourtellari, Stephanie Luttosch, Katharina Hannemann, Stefanie Koristka, Liliana R. Loureiro, Anja Feldmann, Torsten Tonn, Torsten Tonn, Torsten Tonn, Theresa Link, Theresa Link, Theresa Link, Jan Dominik Kuhlmann, Jan Dominik Kuhlmann, Jan Dominik Kuhlmann, Pauline Wimberger, Pauline Wimberger, Pauline Wimberger, Michael Philipp Bachmann, Michael Philipp Bachmann, Michael Philipp Bachmann, Michael Philipp Bachmann, Marc Schmitz, Marc Schmitz, Marc Schmitz   +33 more
doaj   +1 more source

AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma

Medicinal Research Reviews, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo, Kaeun Chae, Jueun Lee, Inseon Kim, Seunghun S. Lee   +4 more
wiley   +1 more source

Aptamer–Based Targeted Protein Degradation: Mechanistic Principles, Delivery Strategies, and Translational Opportunities

Medicinal Research Reviews, EarlyView.
ABSTRACT Targeted elimination of pathogenic proteins remains a fundamental challenge in therapeutic intervention, particularly for proteins considered “undruggable” by conventional inhibition‐based approaches. Aptamer–based targeted protein degradation (TPD) has emerged as a versatile strategy that leverages the high specificity, structural ...
Ambrin Malik, Suyeon Son, Jaesung Lee, Ki Soo Park   +3 more
wiley   +1 more source

Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target

Cell Communication and Signaling, 2019
Background Chondrosarcoma is a malignant cartilaginous neoplasm of the bone which resistant to radiation therapy and chemotherapy. Cyclin-dependent kinase 4 (CKD4) is highly expressed in human cancer, and palbociclib, the inhibitor of CDK4 has been used ...
Zhengxiao Ouyang, Sisi Wang, Ming Zeng, Zhihong Li, Qing Zhang, Wanchun Wang, Tang Liu   +6 more
doaj   +1 more source

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source